Minerva Neurosciences | NERV - Assets


Minerva Neurosciences reported $97.97M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Adma Biologics USD 732.48M 48.28M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
AstraZeneca USD 119.92B 4.09B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cipla INR 434.34B 9.38B Sep/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 148.07B 5.79B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 197.42B 3.64B Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Novavax USD 888M 67.57M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025